Cargando…

New treatments and new assessment instruments for Hidradenitis suppurativa

Research interest in Hidradenitis Suppurativa (HS) has grown exponentially over the past decades. Several groups have worked to develop novel scores that address the drawbacks of existing investigator‐assessed and patient‐reported outcome measures currently used in HS trials, clinical practice and r...

Descripción completa

Detalles Bibliográficos
Autores principales: van Straalen, Kelsey R., Ingram, John R., Augustin, Matthias, Zouboulis, Christos C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542859/
https://www.ncbi.nlm.nih.gov/pubmed/35582833
http://dx.doi.org/10.1111/exd.14609
_version_ 1784804246514827264
author van Straalen, Kelsey R.
Ingram, John R.
Augustin, Matthias
Zouboulis, Christos C.
author_facet van Straalen, Kelsey R.
Ingram, John R.
Augustin, Matthias
Zouboulis, Christos C.
author_sort van Straalen, Kelsey R.
collection PubMed
description Research interest in Hidradenitis Suppurativa (HS) has grown exponentially over the past decades. Several groups have worked to develop novel scores that address the drawbacks of existing investigator‐assessed and patient‐reported outcome measures currently used in HS trials, clinical practice and research. In clinical trial settings, the drawbacks of the HiSCR have become apparent; mainly, it is lack of a dynamic measurement of draining tunnels. The newly developed (dichotomous) IHS4 and HASI‐R are backed up by adequate validation data and are good contenders to become the new primary outcome measure in HS clinical trials. Patient‐reported outcomes, as well as physician reported measures, are being developed by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC). For example, the Hidradenitis Suppurativa Quality of Life (HiSQOL) score is a validated measure of HS‐specific quality of life and is already being used in many HS trials. Magnitude of pain measurement via a 0–10 numerical rating scale is well‐established; however, consensus is still required to ensure consistent administration and interpretation of the instrument. A longitudinal measurement over multiple days rather than at one time point, such as for example the Pain Index could provide increased reliability and reduced recall bias. Ultimately, these newly developed scores and tools can be included in a standardized registry to be used in routine clinical practice.
format Online
Article
Text
id pubmed-9542859
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-95428592022-10-14 New treatments and new assessment instruments for Hidradenitis suppurativa van Straalen, Kelsey R. Ingram, John R. Augustin, Matthias Zouboulis, Christos C. Exp Dermatol Special Issue: 11th European Hidradenitis Suppurativa (EHSF) e.V. Conference Research interest in Hidradenitis Suppurativa (HS) has grown exponentially over the past decades. Several groups have worked to develop novel scores that address the drawbacks of existing investigator‐assessed and patient‐reported outcome measures currently used in HS trials, clinical practice and research. In clinical trial settings, the drawbacks of the HiSCR have become apparent; mainly, it is lack of a dynamic measurement of draining tunnels. The newly developed (dichotomous) IHS4 and HASI‐R are backed up by adequate validation data and are good contenders to become the new primary outcome measure in HS clinical trials. Patient‐reported outcomes, as well as physician reported measures, are being developed by the HIdradenitis SuppuraTiva cORe outcomes set International Collaboration (HISTORIC). For example, the Hidradenitis Suppurativa Quality of Life (HiSQOL) score is a validated measure of HS‐specific quality of life and is already being used in many HS trials. Magnitude of pain measurement via a 0–10 numerical rating scale is well‐established; however, consensus is still required to ensure consistent administration and interpretation of the instrument. A longitudinal measurement over multiple days rather than at one time point, such as for example the Pain Index could provide increased reliability and reduced recall bias. Ultimately, these newly developed scores and tools can be included in a standardized registry to be used in routine clinical practice. John Wiley and Sons Inc. 2022-09-04 2022-09 /pmc/articles/PMC9542859/ /pubmed/35582833 http://dx.doi.org/10.1111/exd.14609 Text en © 2022 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Special Issue: 11th European Hidradenitis Suppurativa (EHSF) e.V. Conference
van Straalen, Kelsey R.
Ingram, John R.
Augustin, Matthias
Zouboulis, Christos C.
New treatments and new assessment instruments for Hidradenitis suppurativa
title New treatments and new assessment instruments for Hidradenitis suppurativa
title_full New treatments and new assessment instruments for Hidradenitis suppurativa
title_fullStr New treatments and new assessment instruments for Hidradenitis suppurativa
title_full_unstemmed New treatments and new assessment instruments for Hidradenitis suppurativa
title_short New treatments and new assessment instruments for Hidradenitis suppurativa
title_sort new treatments and new assessment instruments for hidradenitis suppurativa
topic Special Issue: 11th European Hidradenitis Suppurativa (EHSF) e.V. Conference
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542859/
https://www.ncbi.nlm.nih.gov/pubmed/35582833
http://dx.doi.org/10.1111/exd.14609
work_keys_str_mv AT vanstraalenkelseyr newtreatmentsandnewassessmentinstrumentsforhidradenitissuppurativa
AT ingramjohnr newtreatmentsandnewassessmentinstrumentsforhidradenitissuppurativa
AT augustinmatthias newtreatmentsandnewassessmentinstrumentsforhidradenitissuppurativa
AT zouboulischristosc newtreatmentsandnewassessmentinstrumentsforhidradenitissuppurativa